Literature DB >> 7070779

Miotics: side effects and ways to avoid them.

T J Zimmerman, T M Wheeler.   

Abstract

Pilocarpine, a parasympathomimetic drug used in the treatment of glaucoma, produces a variety of ocular and systemic adverse reactions. Ocular side effects include miosis, accommodative spasm, frontal headaches, twitching lids, conjunctival injection, cataractous changes, allergic reactions, iris cysts, retinal detachment, increased permeability of the blood-aqueous barrier, anterior chamber narrowing, and the potential for inducing an acute angle-closure attack. Systemic side effects include nausea, vomiting, tenesmus, abdominal spasm, salivation, lacrimation, sweating, pulmonary edema, and bronchial spasm. The systemic side effects can best be minimized initially through proper use of the medication and nasolacrimal occlusion. The Ocusert, a long-acting pilocarpine-incorporated ocular insert, is a recent advance in delivery technique that offers an adequate hypotensive action with fewer side effects. Pilopex is a promising new experimental pilocarpine polymer salt presently being studied in Israel. Photomydriasis, a process involving the use of a laser to enlarge miotic pupils also offers help for these patients. N-demethylated carbachol is a new parasympathomimetic drug currently under study for glaucoma therapy. Initial results show that it may have considerable ocular hypotensive action with fewer adverse effects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7070779     DOI: 10.1016/s0161-6420(82)34866-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  12 in total

Review 1.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

Review 2.  Topical drug therapy in glaucoma.

Authors:  Hemma Resch; Gerhard Garhofer
Journal:  Wien Med Wochenschr       Date:  2006-09

3.  The effect of nasolacrimal occlusion on drug-induced mydriasis.

Authors:  A Loewenstein; A Sadeh; M Goldstein; M Lazar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-08       Impact factor: 3.117

Review 4.  Age-related cataracts: Role of unfolded protein response, Ca2+ mobilization, epigenetic DNA modifications, and loss of Nrf2/Keap1 dependent cytoprotection.

Authors:  Palsamy Periyasamy; Toshimichi Shinohara
Journal:  Prog Retin Eye Res       Date:  2017-08-31       Impact factor: 21.198

Review 5.  Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.

Authors:  Angelo P Tanna; Mark Johnson
Journal:  Ophthalmology       Date:  2018-07-12       Impact factor: 12.079

6.  Present and New Treatment Strategies in the Management of Glaucoma.

Authors:  Kolko M
Journal:  Open Ophthalmol J       Date:  2015-05-15

7.  Presbyopia: a new potential pharmacological treatment.

Authors:  Jorge Benozzi; Giovanna Benozzi; Betina Orman
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2012

8.  Marine-Steroid Derivative 5α-Androst-3β, 5α, 6β-triol Protects Retinal Ganglion Cells from Ischemia⁻Reperfusion Injury by Activating Nrf2 Pathway.

Authors:  Longxiang Sheng; Bingzheng Lu; Hui Chen; Yun Du; Chen Chen; Wei Cai; Yang Yang; Xuyan Tian; Zhaofeng Huang; Wei Chi; Suizhen Lin; Guangmei Yan; Wei Yin
Journal:  Mar Drugs       Date:  2019-05-05       Impact factor: 5.118

Review 9.  Managing adverse effects of glaucoma medications.

Authors:  Kenji Inoue
Journal:  Clin Ophthalmol       Date:  2014-05-12

10.  Extended pharmacological miosis is superfluous after glaucoma angle surgery: A retrospective study.

Authors:  Hamed Esfandiari; Kiana Hassanpour; Mehdi Yaseri; Nils A Loewen
Journal:  F1000Res       Date:  2018-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.